Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Sponsor Condition of Interest |
---|
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive...
SWOG Cancer Research Network
Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Lung Small Cell Carcinoma
This phase III trial studies magnetic resonance imaging (MRI) surveillance and
prophylactic cranial irradiation (PCI) to see how well they work compared to MRI
surveillance alone in treating patients with small cell lung cancer. MRI scans are used
to monitor the possible spread of the cancer with... expand
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans. Type: Interventional Start Date: May 2020 |
PRP Injections for Genitourinary Syndrome of Menopause
Medstar Health Research Institute
PRP
Sexual Function Disturbances
Genitourinary Syndrome of Menopause
Postmenopausal Symptoms
Vaginal Atrophy
Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the
supernatant resulting in a solution with high concentration of platelets. Injection of
PRP stimulates cell growth and can has been proven safe and effective for uses in
orthopedics, dermatology, and gynecology.... expand
Platelet-rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. Injection of PRP stimulates cell growth and can has been proven safe and effective for uses in orthopedics, dermatology, and gynecology. Despite the relative paucity of data, the use of PRP as a therapy for sexual dysfunction and genitourinary symptoms in the setting of menopause has been patented as the O-Shot and V-Shot. This is a single-blinded randomized control trial to determine if PRP injections into the anterior vaginal wall improve sexual functioning in women diagnosed with the genitourinary syndrome of menopause (GSM) characterized by vaginal dryness/irritation. Type: Interventional Start Date: Mar 2024 |
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close...
ECOG-ACRIN Cancer Research Group
Prostate Carcinoma
This phase II trial studies how well green tea catechins work in preventing progression
of prostate cancer from a low risk stage to higher risk stages in men who are on active
surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of
prostate growing. expand
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing. Type: Interventional Start Date: Oct 2021 |
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small...
Genentech, Inc.
Non-small Cell Lung Cancer
This trial will evaluate the efficacy and safety of various therapies in patients with
Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung
cancer (NSCLC) tumors that meet protocol-specified biomarker criteria expand
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria Type: Interventional Start Date: Nov 2020 |
Tobacco Education and Lung Health Study (TEAL)
Georgetown University
Smoking Cessation
Primary Objective To compare two smoking cessation interventions among individuals
undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence
from cigarettes and 6-month self-reported and bioverified abstinence from cigarettes.
Secondary Objectives 1) To evaluate reach... expand
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinence from cigarettes. Secondary Objectives 1) To evaluate reach and engagement overall and by subgroup (e.g., race and ethnicity, underinsured, readiness to quit). 2) To conduct an economic analysis to evaluate intervention costs from the health system perspective. Type: Interventional Start Date: Feb 2024 |
Cold Agglutinin Disease Real World Evidence Registry
Sanofi
Cold Agglutinin Disease (CAD)
Cold Agglutinin Syndrome (CAS)
This is a multinational, multi-center, observational, prospective, longitudinal disease
registry designed to collect data on participants with cold agglutinin disease (CAD) or
cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated
with sutimlimab are expected to take... expand
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry. Type: Observational [Patient Registry] Start Date: Dec 2019 |
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid...
Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
The purpose of this study is to evaluate the safety and tolerability of extended dosing
with eplontersen in participants with ATTR-CM. expand
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM. Type: Interventional Start Date: Nov 2022 |
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
Penumbra Inc.
Deep Vein Thrombosis
DVT
The objective of this study is to demonstrate the safety and efficacy of the Indigo
Aspiration system for percutaneous mechanical thrombectomy in a population presenting
with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment. expand
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment. Type: Interventional Start Date: Sep 2021 |
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Abramson Cancer Center at Penn Medicine
Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or
Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are
found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive
surgery and standard adjuvant therapy. expand
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy. Type: Interventional Start Date: Jun 2021 |
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
University of Maryland, Baltimore
Locally Advanced Pancreatic Cancer
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy
drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton
therapy for the treatment of locally advanced pancreatic cancer. You will receive proton
therapy once a day (Monday - Friday)... expand
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks. Type: Interventional Start Date: Apr 2019 |
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma...
Georgetown University
Pancreatic Ductal Adenocarcinoma
Refractory Non-Small Cell Lung Cancer
The goal of this clinical trial is to test the safety and tolerability of anti-CD38
monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax
TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb
(nivolumab) in patients with advanced non-small... expand
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: - How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? - How well does participants bodies handle these study drugs? - Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs. Type: Interventional Start Date: Jan 2024 |
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal...
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
Prospective, non-randomized, , multicenter study with two independent arms:
- Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System.
Hypothesis-driven analysis.
- Up to 65 additional subjects may be implanted in Continued Access Phase under
the... expand
Prospective, non-randomized, , multicenter study with two independent arms: - Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. - Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only - Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted in Continued Access (Primary Study arm) Type: Interventional Start Date: Jun 2019 |
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3...
Turning Point Therapeutics, Inc.
Locally Advanced Solid Tumors
Metastatic Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs),
the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2
dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies
harboring an ALK, ROS1, NTRK1, NTRK2,... expand
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Type: Interventional Start Date: Mar 2017 |
Integrated Cancer Repository for Cancer Research
University of Nebraska
Pancreatic Cancer
Thyroid Cancer
Lung Cancer
Esophageal Cancer
Thymus Cancer
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela
Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal
data and biospecimens on consented adult cancer patients, high-risk individuals, and
normal controls. The distinct characteristic... expand
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Type: Observational [Patient Registry] Start Date: Nov 2013 |
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
CHDI Foundation, Inc.
Huntington's Disease
Enroll-HD is a longitudinal, observational, multinational study that integrates two
former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North
America and Australasia-while also expanding to include sites in Latin America. More than
30,000 participants have now enrolled into... expand
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more. Type: Observational [Patient Registry] Start Date: Jul 2012 |
Linezolid for Syphilis Pilot Study
University of Southern California
Syphilis
The study aims to evaluate the efficacy of linezolid for the treatment of syphilis. expand
The study aims to evaluate the efficacy of linezolid for the treatment of syphilis. Type: Interventional Start Date: Sep 2023 |
Intraperitoneal Infusion of Analgesic for Postoperative Pain Management
Ying Liu
Hysterectomy
Gynecologic Surgical Procedures
Narcotic Use
Pain, Postoperative
The study is a prospective, double-blinded, placebo-controlled multi-center trial to
measure if postoperative pain and the amount of narcotics used are reduced by a
clinically significant amount in women undergoing minimally invasive hysterectomy
receiving a continuous infusion of intraperitoneal... expand
The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline. Type: Interventional Start Date: Sep 2019 |
Device Feasibility and Acceptability to Improve Insomnia in Cancer
Medstar Health Research Institute
Cancer
Insomnia Chronic
Sleep disruption is common among young adult cancer survivors for a variety of reasons.
Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve chronic sleep
disorders. This project will test the feasibility and acceptability of a new
voice-activated virtual assistant (VAVA) device... expand
Sleep disruption is common among young adult cancer survivors for a variety of reasons. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve chronic sleep disorders. This project will test the feasibility and acceptability of a new voice-activated virtual assistant (VAVA) device to deliver CBT-I to improve sleep among young adult cancer survivors with chronic sleep disorders. Type: Interventional Start Date: Jul 2023 |
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield...
Mercator MedSystems, Inc.
Iliofemoral; Thrombosis
This is a study of a medical procedure that utilizes a commercially available catheter
(the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available
anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins
after DVT recanalization, where DVT symptoms... expand
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure. Type: Interventional Start Date: Aug 2022 |
A Balanced Reach Training Platform to Address Balance Disorders in Older and Neurologically Disabled...
VA Office of Research and Development
Older Men and Women With High Fall Risk
Falls are by far the leading cause of accidental injury and death in older adults. The
Veteran population is more severely affected by falls since it is significantly older
than the overall population (45% over 65 years of age vs. 13%); and Veterans would
benefit substantially more from an accurate... expand
Falls are by far the leading cause of accidental injury and death in older adults. The Veteran population is more severely affected by falls since it is significantly older than the overall population (45% over 65 years of age vs. 13%); and Veterans would benefit substantially more from an accurate diagnosis and treatment of fall propensity. Despite its importance, much is still unknown about the manner in which balance control is compromised by age and disease. Therapeutic interventions for people who are at risk of falling have proven to be of limited utility. Engineering methods are well suited to study and evaluate balance; but have to date been applied to overly simplified scenarios that lack the complexity to probe the musculoskeletal and neurophysiological bases for balance and falls. The long term objective of this research, which began with a VA Rehabilitation Research & Development (RR&D) Career Development Award (CDA-2), is to develop improved directives and protocols for the diagnosis and treatment of balance-related posture and movement coordination problems. This proposal significantly advances engineering methods to address existing gaps in the diagnosis and treatment of balance impairments through the development of a Balanced Reach Training Protocol (BRTP). The BRTP continuously challenges subjects to perform reaching tasks at the limits of their balance for an extended period of time, and increases these limits as subjects demonstrate improved performance. The goal of this tool is to quantitatively assess and improve at-risk individuals' ability to maintain balance when disturbed by volitional movements of the body and its parts-an important class of balance disturbances integral to many activities of daily living that can precipitate falls. The BRTP focuses on performance at and just beyond the limits of balance, unlike most such tests and training protocols that do not challenge subjects in this way. The BRTP's most immediate and salient metric is the limiting boundary of standing reach; and we hypothesize that expanding this boundary, as the BRTP is designed to do, will improve balance and make individuals more resistant to falls (in the context of expected balance disturbances). Confirmation of this hypothesis could provide a new perspective on existing training protocols' modest success rates, and direction for the design of new protocols with the potential to significantly improve these rates. [Though the BRTP is a training platform, we also believe that the performance metrics and analytical results produced by it can form the basis for new diagnostic measures that more reliably and precisely quantify and explain balance performance problems; and track changes in them over time.] Such diagnostic and treatment protocols would be particularly beneficial to the VA Health Care System, as it would lead to improvements in: patient throughput, quality of care, and treatment costs. Though this proposal targets the aging Veteran population, the BRTP is a general tool that can aid in the diagnosis and treatment of balance disorders arising from conditions other than aging. These include obesity, diabetes (which often leads to lower extremity muscle degeneration and peripheral neuropathy), sarcopenia, vestibular disorders, and neurological disorders such as stroke. Veterans whose balance has been compromised by Traumatic Brain Injury (TBI) (whether combat-related or not) may also benefit from the BRTP. Type: Observational Start Date: Nov 2021 |
Reshaping Postpartum Follow-up
Medstar Health Research Institute
Hypertension in Pregnancy
Gestational Diabetes
Cervical Dysplasia
The aim of this study is to evaluate the impact of personalized postpartum follow-up
cards on completion of postpartum health related tasks. The intervention will consist of
a card given to patients at time of discharge. One side of the card will list the
patient's name and a list of recommended postpartum... expand
The aim of this study is to evaluate the impact of personalized postpartum follow-up cards on completion of postpartum health related tasks. The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. Participants will be randomized to this intervention or the control group, which will consist of standard education routinely given at discharge. The primary endpoint will be the rate of completion of a postpartum blood pressure check or two hour glucose tolerance test, or both, depending on the patient's discharge diagnosis within the first year after discharge. The secondary endpoints will include establishing care with a primary care provider within the first year after delivery, or completion of postpartum pap smear or colposcopy, as indicated. Type: Interventional Start Date: May 2023 |
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Massachusetts General Hospital
Myocarditis Acute
Cancer
The primary aim is to test whether abatacept, as compared to placebo, is associated with
a reduction in major adverse cardiac events (MACE) among participants hospitalized with
myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE,
is a composite of first occurrence... expand
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure. Type: Interventional Start Date: Jun 2022 |
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
Adaptive Phage Therapeutics, Inc.
Osteomyelitis
Diabetic Foot Osteomyelitis
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in
patients with diabetic foot osteomyelitis. expand
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis. Type: Interventional Start Date: Nov 2021 |
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome
Viral or Bacterial Infections
Pneumonia
Pneumonia, Viral
Respiratory Infection
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study
in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen
therapy. The purpose of this study is to examine the safety, tolerability and efficacy of
AV-001 Injection administration daily... expand
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Type: Interventional Start Date: Dec 2021 |
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
Georgetown University
Lung Cancer
To test the impact of a multilevel intervention on primary (provider-patient
communication, intentions, and knowledge) and secondary (screening referrals and
completion) outcomes. expand
To test the impact of a multilevel intervention on primary (provider-patient communication, intentions, and knowledge) and secondary (screening referrals and completion) outcomes. Type: Interventional Start Date: Feb 2024 |
- Previous
- Next